Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
Journal of Hematology & Oncology, 2012 The diverse pathways and molecules involved in angiogenesis, the formation of new blood vessels, have been targeted for the treatment of colorectal and other cancers.
Sun Weijing
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Background: Association of drugs acting against different antiangiogenic mechanisms may increase therapeutic effect and reduce resistance. Noninvasive monitoring of changes in the antiangiogenic response of individual tumors could guide selection and ...
Michele Lamuraglia MD, PhD +8 more
doaj +1 more source
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]
, 2021 Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina +11 more
core +1 more source
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. [PDF]
Int J Retina Vitreous, 2016 In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences.
de Oliveira Dias JR +4 more
europepmc +4 more sources
Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer [PDF]
, 2014 PURPOSE: Development of new therapies for previously treated small-cell lung cancer (SCLC) is a major unmet need. Here, we describe a randomized, phase II trial of weekly topotecan with or without ziv-aflibercept (VEGF-trap) in this clinical setting ...
Jahanzeb, Mohammad +9 more
core +1 more source
Progression of Ziv-aflibercept on metastatic colorectal cancer [PDF]
, 2015 针对特异性分子靶点的靶向药物治疗已成为转移性结直肠癌(M CrC)治疗的新方向。2012年zIV-阿柏西普被美国食品和药物管理局批准用于M CrC患者,zIV-阿柏西普是一种作用于血管生成信号通路的重组融合蛋白,通过与血管内皮生长因子(VEgf)受体结合,从而阻断肿瘤的生长和转移。一项Ⅲ期临床研究结果显示zIV-阿柏西普能显著延长M CrC患者的生存期。本文结合国内外最新研究报道,对zIV-阿柏西普治疗M CrC的研究进展作一综述。Targeted drug therapy for specific ...
宋敏
core
Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema [PDF]
, 2017 Purpose We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). Methods Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (
Mansour, Ahmad Mohammed Farid Mahmoud +2 more
core +1 more source
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer
World Journal of Clinical Oncology, 2014 Ziv-afilbercept (Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor (VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG1. Recently, a randomized, open-label, phase III study compared 5-fluorouracil, leucovorin, irinotecan (FOLFIRI)/Ziv with FOLFIRI ...
Muhammad Wasif, Saif +3 more
openaire +2 more sources
Baseline characteristics of 20 eyes on treatment with intravitreal ziv-aflibercept.
, 2019 Baseline characteristics of 20 eyes on treatment with intravitreal ziv-aflibercept.
Stephen Akafo (348360) +5 more
core +1 more source
Delta Journal of OphthalmologyPurpose The aim of this study was to evaluate the efficacy of intravitreal injection of Ziv-aflibercept before small-gauge pars plana vitrectomy compared to pars plana vitrectomy alone in eyes with advanced diabetic eye disease. Patients and methods
Amin E. Nawar, Ahmed R. Alagorie
doaj +1 more source